Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE AND ESTRADIOL versus SAFYRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE AND ESTRADIOL versus SAFYRAL.
DROSPIRENONE AND ESTRADIOL vs SAFYRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity; estradiol is an estrogen. Drospirenone acts as a progesterone receptor agonist, inhibits ovulation, and increases cervical mucus viscosity. Estradiol replaces endogenous estrogen, suppresses gonadotropin secretion.
Safyral is a combination of ethinyl estradiol and drospirenone. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, preventing ovulation. Drospirenone is a progestin with anti-mineralocorticoid activity, which may reduce fluid retention, and anti-androgenic activity, which may improve acne. It also increases cervical mucus viscosity, impeding sperm penetration.
One tablet (drospirenone 3 mg / estradiol 0.5 mg) orally once daily for hormone therapy.
One tablet (drospirenone 3 mg/ethinyl estradiol 0.03 mg) orally once daily for 24 days, followed by 4 days of placebo.
None Documented
None Documented
Drospirenone: ~30-40 hours (allows once-daily dosing); estradiol: ~12-15 hours (after oral administration).
16.3 hours (range 12-21 hours) for drospirenone; 32.5 hours (range 24-42 hours) for ethinyl estradiol (EE); clinical context: steady-state achieved after 10 days for drospirenone, 7 days for EE
Drospirenone: ~40-50% renal, ~50-60% fecal; estradiol: ~60-80% renal (as metabolites), ~20-40% fecal.
Urine (40% as metabolites, 20% unchanged; fecal 30% as metabolites; biliary excretion contributes to enterohepatic circulation, prolonging elimination)
Category D/X
Category C
Estrogen
Oral Contraceptive Progestin/Estrogen